Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of HR17031 in Liver Impairment
NCT05151705Phase 1Unknown
- Sponsor
- Hengrui
- Start
- Dec 2021
- Primary completion
- Jun 2022
- Modality
- Peptides, Recombinant Proteins and Enzymes, Small Molecules
01
Overview
Phase 1, open-label trial of HR17031 in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Hengrui. Primary endpoints: Maximum Plasma Concentration, Area Under the Curve from time 0 to last measurable concentration and 1 more. Status: unknown.
02
Drugs
HR17031
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05151705.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05151705.